Emodin enhances ATRA-induced differentiation and induces apoptosis in acute myeloid leukemia cells

Chen,Yingyu; Li,Jing; Hu,Jianda; Zheng,Jing; Zheng,Zhihong; Liu,Tingbo; Lin,Zhenxing; Lin,Minhui

doi:10.3892/ijo.2014.2610

Emodin enhances ATRA-induced differentiation and induces apoptosis in acute myeloid leukemia cells

Authors:
- Yingyu Chen
- Jing Li
- Jianda Hu
- Jing Zheng
- Zhihong Zheng
- Tingbo Liu
- Zhenxing Lin
- Minhui Lin
View Affiliations

Affiliations: Fujian Medical University Union Hospital, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fuzhou 350001, Fujian, P.R. China
Published online on: August 19, 2014 https://doi.org/10.3892/ijo.2014.2610
Pages: 2076-2084

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Emodin, an extracted natural compound from the root and rhizome of Rheum palmatum L, has been shown to have multiple biological activities including anticancer functions in previous studies. In this study, we investigated the anti-leukemic activity of emodin alone or emodin in the presence all-trans retinoic acid (ATRA) in acute myeloid leukemia (AML) cells and the potential signaling pathway involved. We demonstrated that emodin could significantly enhance the sensitivity to ATRA and present additive differentiation-inducing effects in AML cell line NB4 cells and, especially, in NB4-derived ATRA-resistant MR2 cells. Further study showed that increasing dose of emodin could effectively induce growth inhibition and apoptotic effects in both cell lines as well as in primary leukemic cells from AML patients. Moreover, the apoptotic induction in AML cells was associated with the activation of caspase cascades involving caspase-9, caspase-3, and poly(ADP-ribose) polymerase (PARP) cleavage. In addition, leukemic cell response to emodin stimuli in vitro was observed through the decreased expression levels of Bcl-2 and retinoic acid receptor α (RARα). Importantly, emodin was demonstrated as a new inhibitor of PI3K/Akt in AML cells, even in primary AML cells. It inhibited Akt phosphoration (p-Akt) at Ser473 as efficiently as mTOR at Ser2448. Consistently, it exerted suppression effects on the phosphoration of mTOR downstream targets, 4E-BP1 and p70S6K. Taken together, these findings indicate that emodin might be developed as a promising anti-leukemic agent to improve the patient outcome in AML.

View Figures

View References

1	Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al: Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 115:453–474. 2010. View Article : Google Scholar : PubMed/NCBI
2	Zhou GB, Zhang J, Wang ZY, Chen SJ and Chen Z: Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc of Lond B Biol Sci. 362:959–971. 2007. View Article : Google Scholar : PubMed/NCBI
3	West KA, Castillo SS and Dennis PA: Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat. 5:234–248. 2002. View Article : Google Scholar : PubMed/NCBI
4	Franke TF, Hornik CP, Segev L, Shostak GA and Sugimoto C: PI3K/Akt and apoptosis: size matters. Oncogene. 22:8983–8998. 2003. View Article : Google Scholar
5	Xu Q, Simpson SE, Scialla TJ, Bagg A and Carroll M: Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood. 102:972–980. 2003. View Article : Google Scholar : PubMed/NCBI
6	Tamburini J, Chapuis N, Bardet V, et al: Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood. 111:379–382. 2008. View Article : Google Scholar
7	Zeng Z, Shi YX, Tsao T, et al: Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood. 120:2679–2689. 2012. View Article : Google Scholar : PubMed/NCBI
8	Shrimali D, Shanmugam MK, Kumar AP, et al: Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer. Cancer Lett. 341:139–149. 2013. View Article : Google Scholar : PubMed/NCBI
9	Wu L, Cai B, Zheng S, Liu X, Cai H and Li H: Effect of emodin on endoplasmic reticulum stress in rats with severe acute pancreatitis. Inflammation. 36:1020–1029. 2013. View Article : Google Scholar : PubMed/NCBI
10	de Tamokou JD, Chouna JR, Fischer-Fodor E, et al: Anticancer and antimicrobial activities of some antioxidant-rich Cameroonian medicinal plants. PloS One. 8:e558802013.PubMed/NCBI
11	Zhang L, Lau YK, Xia W, Hortobagyi GN and Hung MC: Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res. 5:343–353. 1999.
12	Brown M, Bellon M and Nicot C: Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1. Blood. 109:1653–1659. 2007. View Article : Google Scholar : PubMed/NCBI
13	Wei WT, Chen H, Ni ZL, et al: Antitumor and apoptosis-promoting properties of emodin, an anthraquinone derivative from Rheum officinale Baill, against pancreatic cancer in mice via inhibition of Akt activation. Int J Oncol. 39:1381–1390. 2011.PubMed/NCBI
14	Huang LY, Hu JD, Chen XJ, Zhu LF and Hu HL: Effects of emodin on the proliferation inhibition and apoptosis induction in HL-60 cells and the involvement of c-myc gene. Zhonghua Xue Ye Xue Za Zhi. 26:348–351. 2005.PubMed/NCBI
15	Chen YY, Zheng HY, Hu JD, et al: Inhibitory effects of emodin on drug-resistant HL-60/ADR cell proliferation and its induction of apoptosis. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 15:955–960. 2007.PubMed/NCBI
16	Chen YY, Li J, Hu JD, et al: Reversing effects of emodin on multidrug resistance in resistant HL-60/ADR cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 21:1413–1422. 2013.PubMed/NCBI
17	Lin M, Hu J, Liu T, Li J, Chen B and Chen X: Knockdown of nucleophosmin by RNA interference reverses multidrug resistance in resistant leukemic HL-60 cells. Immunobiology. 218:1147–1154. 2013. View Article : Google Scholar : PubMed/NCBI
18	Hu J, Lin M, Liu T, Li J, Chen B and Chen Y: DIGE-based proteomic analysis identifies nucleophosmin/B23 and nucleolin C23 as over-expressed proteins in relapsed/refractory acute leukemia. Leuk Res. 35:1087–1092. 2011. View Article : Google Scholar : PubMed/NCBI
19	Tamburini J, Elie C, Bardet V, et al: Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood. 110:1025–1028. 2007. View Article : Google Scholar
20	Martelli AM, Evangelisti C, Chiarini F and McCubrey JA: The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget. 1:89–103. 2010.PubMed/NCBI
21	Grandage VL, Gale RE, Linch DC and Khwaja A: PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia. 19:586–594. 2005.PubMed/NCBI
22	Niu C, Yan H, Yu T, et al: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 94:3315–3324. 1999.
23	Mathews V, George B, Chendamarai E, et al: Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 28:3866–3871. 2010. View Article : Google Scholar : PubMed/NCBI
24	Ghavamzadeh A, Alimoghaddam K, Rostami S, et al: Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 29:2753–2757. 2011. View Article : Google Scholar : PubMed/NCBI
25	Ma YN, Chen MT, Wu ZK, et al: Emodin can induce K562 cells to erythroid differentiation and improve the expression of globin genes. Mol Cell Biochem. 382:127–136. 2013. View Article : Google Scholar : PubMed/NCBI
26	Muto A, Hori M, Sasaki Y, et al: Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol Cancer Ther. 6:987–994. 2007. View Article : Google Scholar : PubMed/NCBI
27	Yan Y, Su X, Liang Y, et al: Emodin azide methyl anthraquinone derivative triggers mitochondrial-dependent cell apoptosis involving in caspase-8-mediated Bid cleavage. Mol Cancer Ther. 7:1688–1697. 2008. View Article : Google Scholar
28	Tauchi T, Sumi M, Nakajima A, Sashida G, Shimamoto T and Ohyashiki K: BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Clin Cancer Res. 9:4267–4273. 2003.PubMed/NCBI
29	Kim R, Emi M, Tanabe K and Toge T: Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma. Cancer. 101:2177–2186. 2004. View Article : Google Scholar : PubMed/NCBI
30	Karnak D and Xu L: Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Current Drug Targets. 11:699–707. 2010. View Article : Google Scholar : PubMed/NCBI
31	Parrondo R, de Las Pozas A, Reiner T and Perez-Stable C: ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells. PeerJ. 1:e1442013. View Article : Google Scholar : PubMed/NCBI
32	Nasr R, Guillemin MC, Ferhi O, et al: Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med. 14:1333–1342. 2008. View Article : Google Scholar : PubMed/NCBI
33	Hu J, Liu YF, Wu CF, et al: Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 106:3342–3347. 2009. View Article : Google Scholar : PubMed/NCBI
34	Isakson P, Bjoras M, Boe SO and Simonsen A: Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood. 116:2324–2331. 2010. View Article : Google Scholar : PubMed/NCBI
35	Zhang XW, Yan XJ, Zhou ZR, et al: Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science. 328:240–243. 2010. View Article : Google Scholar : PubMed/NCBI
36	Harris MN, Ozpolat B, Abdi F, et al: Comparative proteomic analysis of all-trans-retinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute promyelocytic leukemia. Blood. 104:1314–1323. 2004. View Article : Google Scholar
37	Bayascas JR and Alessi DR: Regulation of Akt/PKB Ser473 phosphorylation. Mol Cell. 18:143–145. 2005. View Article : Google Scholar : PubMed/NCBI
38	Sarbassov DD, Guertin DA, Ali SM and Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI